Tirzepatide or Retatrutide? Comparing Two Generations of GLP-1-Based Metabolic Research

Tirzepatide or retatrutide — which is better? It is one of the most common questions in metabolic research discussions, and at first glance the comparison seems straightforward. Both target the GLP-1 pathway, both have produced substantial weight reductions in trials, and both sit at the centre of the current research conversation.

But an important distinction tends to get lost: tirzepatide is an approved medication with years of Phase 3 and post-marketing data behind it, while retatrutide remains an investigational compound. That changes what the comparison can legitimately say.

This piece follows the structure of Ed Parker's write-up "Tirzepatide or Retatrutide? Comparing Two Generations of GLP-1–Based Metabolic Research" (31 August 2026), with the underlying trial figures re-checked against the published readouts.

Research use only. Retatrutide is an investigational compound and is not approved for general use. Everything below describes clinical and laboratory findings. Nothing here is medical advice or a recommendation for human use.

First: they are not the same drug

Tirzepatide is a dual GIP/GLP-1 receptor agonist — it activates the GIP receptor and the GLP-1 receptor. It is marketed as Zepbound (chronic weight management) and Mounjaro (type 2 diabetes) in the United States.

Retatrutide goes one step further: a triple receptor agonist targeting GIP, GLP-1 and glucagon. That third pathway is the reason for the excitement. Glucagon-receptor signalling introduces effects involving energy metabolism, substrate utilisation and energy expenditure — mechanisms being investigated alongside the appetite and glucose effects associated with GIP and GLP-1.

So while the two compounds overlap, they are not interchangeable.

Why retatrutide gets so much attention

The simplest explanation is the magnitude of the results so far.

In the 2023 Phase 2 obesity trial published in the New England Journal of Medicine, mean weight change at 48 weeks ranged from 8.7% at the lowest studied dose to 24.2% at the highest, versus 2.1% with placebo. At the highest dose, 83% of participants lost at least 15% of body weight and 26% lost at least 30%.

Those numbers are remarkable — but they need context. This was a Phase 2 trial with carefully selected, closely monitored participants. A headline trial number does not translate directly into an individual result.

Tirzepatide has already produced major results

Tirzepatide should not be dismissed simply because retatrutide looks promising.

In the landmark SURMOUNT-1 Phase 3 trial (2,539 adults, 72 weeks), average weight reduction was 15.0% at 5 mg, 19.5% at 10 mg and 20.9% at 15 mg, versus 3.1% with placebo — alongside improvements in prespecified cardiometabolic measures. And in the head-to-head SURMOUNT-5 trial, tirzepatide produced greater average weight loss than semaglutide over 72 weeks: 20.2% versus 13.7%.

The question was never whether tirzepatide works. The interesting question is whether retatrutide's additional glucagon activity can push metabolic efficacy further.

The "food noise" question

"Food noise" — persistent thoughts about eating, cravings and preoccupation with highly rewarding foods — comes up constantly in community discussions.

Many anecdotal reports suggest tirzepatide feels particularly strong for appetite suppression. That is plausible pharmacologically: its GLP-1 activity influences appetite and food intake, with GIP signalling adding a further metabolic component.

But two cautions apply:

• There is not enough direct evidence to claim tirzepatide universally suppresses food noise better than retatrutide.
• "Food noise" is not a standardised clinical endpoint, so the two compounds cannot be ranked on it with the precision online discussions often claim.

Retatrutide may be doing something different

Retatrutide is not simply trying to reduce intake. Its glucagon component may contribute to changes in energy expenditure and substrate utilisation, and the Phase 2 researchers specifically discussed glucagon-receptor activation augmenting the effects of GLP-1 and GIP signalling on energy intake, substrate use and energy expenditure.

That reframes the research question from "how effectively can appetite be suppressed?" to "can appetite, glucose regulation and energy expenditure be influenced simultaneously?" — a considerably bigger metabolic question.

Why the triple-agonist mechanism matters

Think of the three pathways as overlapping pieces of one metabolic system:

• GLP-1: appetite regulation, food intake, glucose regulation, gastrointestinal effects
• GIP: glucose-dependent insulin secretion, nutrient handling, metabolic signalling
• Glucagon: hepatic metabolism, substrate utilisation, energy expenditure, glucose regulation

Retatrutide attempts to activate all three at once. That does not automatically make it "better" — it makes it different and potentially more powerful, and increased pharmacological activity can introduce additional tolerability considerations of its own.

Side effects: both deserve respect

Online claims like "retatrutide has fewer side effects" or "tirzepatide causes worse GI problems" are much too broad.

Both compounds produce gastrointestinal adverse events as their most common category. In the retatrutide Phase 2 trial these were generally mild to moderate, and researchers also reported dose-dependent increases in heart rate that peaked around week 24 and declined afterward. Tirzepatide trials report a similar GI profile, particularly during dose escalation.

The heart-rate observation deserves particular care. An increased heart rate is neither inherently positive (as a possible correlate of energy expenditure) nor inherently negative — it is a physiological change whose clinical meaning has to be established. That is exactly why cardiovascular outcomes trials exist.

The cholesterol distinction

Retatrutide's Phase 2 programme measured lipid parameters, and subsequent analyses have investigated mechanisms linking treatment to changes in circulating lipid-related proteins and serum lipids.

But the caveat matters: a reduction in LDL or triglycerides in a trial is not proof of prevented cardiovascular events. Claims that retatrutide is "better for cardiovascular health" are premature unless tied to dedicated outcomes research.

Which one produces more weight loss?

The temptation is to line up 24.2% (retatrutide Phase 2, highest dose, 48 weeks) against 20.9% (tirzepatide SURMOUNT-1, 15 mg, 72 weeks) and declare a winner.

That is not a valid head-to-head comparison. The trials differ in design, population, duration, dosing, statistical analysis, inclusion criteria and procedures. The only reliable way to rank the two is a properly designed randomised head-to-head trial.

The scientifically accurate answer: retatrutide has produced extremely impressive results in its trials, but it cannot be directly ranked against tirzepatide using separate studies.

Tirzepatide's biggest advantage right now: evidence

From a real-world clinical perspective, tirzepatide has an enormous advantage:

• Regulatory approval
• Established prescribing information
• Large Phase 3 datasets
• Years of clinical experience
• Multiple completed trials and ongoing long-term research

Retatrutide does not have that status. Lilly describes it as an investigational molecule, still being studied across the TRIUMPH and TRANSCEND programmes. That distinction matters enormously.

Retatrutide's biggest advantage: potential

On the research side, retatrutide represents the next step in multi-receptor metabolic pharmacology. The Phase 2 results demonstrated substantial weight reduction, the mechanism is biologically interesting, and the Phase 3 programme is designed to answer the questions Phase 2 could not — including whether the weight-loss signal translates into broader metabolic outcomes, and whether the safety profile holds over longer periods.

So which is "better"?

There is no scientifically responsible one-word answer:

• More established clinical evidence? Tirzepatide.
• Already an approved treatment? Tirzepatide.
• Largest early weight-loss effects? Both are impressive; retatrutide's Phase 2 results are particularly striking.
• Better food-noise suppression? Not enough head-to-head evidence to say.
• Fewer side effects? Not enough evidence for a blanket statement.
• More interesting mechanism? Subjective — but the triple-receptor mechanism is scientifically the more complex.
• Which should an individual choose? A medical decision for a qualified professional — not an internet poll.

The bigger picture

The tirzepatide-versus-retatrutide debate isn't really about two competing products. It's about where metabolic medicine is heading.

The first generation of GLP-1 drugs showed appetite and glucose regulation could be influenced pharmacologically. Tirzepatide combined GIP and GLP-1 signalling. Retatrutide adds glucagon — and researchers are already investigating further receptor combinations.

The question is shifting from "can weight be reduced?" to "how precisely can human metabolism be modulated while maintaining safety, preserving lean tissue and improving long-term health?" For tirzepatide, much of the evidence is already written. For retatrutide, some of the most important answers are still being produced.

Sources

• Jastreboff et al., New England Journal of Medicine — Phase 2 retatrutide obesity trial
• SURMOUNT-1 Phase 3 tirzepatide trial
• SURMOUNT-5 head-to-head tirzepatide vs semaglutide trial
• Eli Lilly TRIUMPH and TRANSCEND Phase 3 programmes
• Ed Parker, "Tirzepatide or Retatrutide? Comparing Two Generations of GLP-1–Based Metabolic Research", 31 August 2026

Research use only. Not for human or veterinary use.